...
首页> 外文期刊>Leukemia and lymphoma >Radiation therapy compared with chemotherapy for consolidation of chemotherapy-induced remission of advanced Hodgkin lymphoma: a study by the Eastern Co-operative Oncology Group (E1476) with >20 years follow-up.
【24h】

Radiation therapy compared with chemotherapy for consolidation of chemotherapy-induced remission of advanced Hodgkin lymphoma: a study by the Eastern Co-operative Oncology Group (E1476) with >20 years follow-up.

机译:放射疗法与化学疗法相结合可巩固由化疗引起的晚期霍奇金淋巴瘤的缓解:一项由东方合作肿瘤小组(E1476)开展的研究,随访时间超过20年。

获取原文
获取原文并翻译 | 示例
           

摘要

MOPP-Bleo (nitrogen mustard, vincristine, procarbazine, prednisone and bleomycin) induction therapy was given to 253 evaluable patients with Hodgkin lymphoma, stages IIIB, III(s), or IV. Complete response (CR) occurred in 145 patients (57%) and partial response (PR) in 93 (37%). Of those 238 responders, 178 were randomized to consolidation therapy, and 164 were eligible and analyzable, including 114 CRs [55 patients randomized to ABVD and 59 to radiation therapy (RT)] and 50 partial responders (PRs) (25 each randomized to ABVD and RT). Among the 50 patients with PR, 34 (68%) converted to CR (16 with ABVD and 18 with RT). Therefore, of 253 patients, 182(72%) achieved CR and 56 (22%), PR. Median follow-up for all patients is 22.3 years and the estimated overall survival (OS) rate at 20 years is 48%. Of the 148 eligible, analyzable patients with CR, the estimated proportion remaining in CR at 20 years is 62%. OS at 20 years was significantly greater for patients receiving ABVD consolidation (66%) when compared with those who received RT consolidation (43%) (p = 0.002). Treatment toxicity was acceptable. After MOPP-Bleo induction for advanced Hodgkin lymphoma, ABVD provides better consolidation than local RT.
机译:对253名可评估的霍奇金淋巴瘤,IIIB,III或IV期患者进行了MOPP-Bleo(氮芥,长春新碱,丙卡巴嗪,泼尼松和博来霉素)诱导治疗。 145例患者(57%)发生完全缓解(CR),93例(37%)发生部分缓解(PR)。在这238位缓解者中,有178位被随机分配到巩固治疗中,有164位符合条件并可以进行分析,包括114位CR(55位患者接受ABVD随机分组和59位接受放射治疗(RT)的患者)和50位部分缓解(PR)(每位25位随机接受ABVD随机分组)和RT)。在50例PR患者中,有34例(68%)转化为CR(ABVD患者16例,RT患者18例)。因此,在253例患者中,有182例(72%)达到了CR,56例(22%)达到了PR。所有患者的中位随访时间为22.3年,预计20年总生存率(OS)为48%。在148例可分析的合格CR患者中,估计20年后仍保留在CR中的比例为62%。与接受RT巩固治疗的患者(43%)相比,接受ABVD巩固治疗的患者20年OS显着更高(66%)(p = 0.002)。治疗毒性是可以接受的。在MOPP-Bleo诱发晚期霍奇金淋巴瘤后,ABVD的局部巩固效果优于局部RT。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号